act017
mAbexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
3
Phase 4
0
Earliest trial started Jan 31, 2019 (NCT03803007)
Timeline
Indications
Mechanism of action
- Platelet glycoprotein VI (GPVI)INHIBITOR
Platelet glycoprotein VI (GPVI) inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650395 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06437431 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2024 | Adolphe Rothschild Ophtalmologic Foundation |
| NCT05559398 | Phase 2/Phase 3 (Phase 3) | Oct 10, 2022 | Assistance Publique - Hôpitaux de Paris |
| NCT05070260 | Phase 2/Phase 3 (Phase 3) | Sep 23, 2021 | Acticor Biotech |
| NCT04659109 | Phase 2 | Dec 31, 2020 | Acticor Biotech |
| NCT03803007 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2019 | Acticor Biotech, Axial Biotech, Inc, Orion Corporation, QPS |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acticor Biotech | For profit | 3 | 3 | 2 | 2019 |
| Adolphe Rothschild Ophtalmologic Foundation | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Axial Biotech, Inc | For profit | 1 | 0 | 1 | 2019 |
| Orion Corporation | For profit | 1 | 0 | 1 | 2019 |
| QPS | For profit | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1